This technology is an immunosuppressant that suppresses T cell proliferation and can be used to treat organ transplant rejection, autoimmune or inflammatory conditions, and modulate the immune and bone microenvironment of multiple myeloma.
T cell proliferation can cause complications with organ transplantation and contribute to autoimmune and inflammatory disease pathology. The immunosuppressant market is growing rapidly, and there is ongoing need for therapeutics that demonstrate long-term slowing of disease progression.
This technology uses peptide fragments derived from matrix metalloproteinase-13 (MMP-13) to modulate immune activity by suppressing T-cell proliferation. These immunosuppressive effects are independent of the enzyme’s catalytic domain. MMP-13 can treat multiple myeloma (MM) bone disease and modulate the MM immune environment by targeting PD-1H–mediated osteoclast activation, which contributes to bone resorption and immune dysregulation.
This technology has been validated in both in vitro and in vivo models of T cell proliferation inhibition.
Patent Pending(US 18/310,702)
IR CU21025
Licensing Contact: Jerry Kokoshka
